

SUPPLEMENTARY TABLE S2. THYROID FINE NEEDLE ASPIRATE IMMUNOPHENOTYPING FOR FURTHER T LYMPHOCYTE ANALYSIS COMPARING IMMUNE CHECKPOINT INHIBITOR THYROIDITIS SAMPLES COLLECTED WITHIN TWO WEEKS OF DIAGNOSIS AND HEALTHY THYROID SAMPLES

<i>Immune cell profile (% of T lymphocytes)</i>	<i>ICI-induced thyroiditis at diagnosis (n=6)</i>	<i>Healthy volunteers (n=3)</i>	<i>Difference of means</i>	<i>p-value (t-test)</i>
CD4 ⁺ CTLA4 ⁺	4.07	27.35	-23.28	0.072
CD4 ⁺ CTLA4 ⁺ CD28 ⁺	19.16	6.92	12.24	0.169
CD4 ⁺ CD28 ⁺	68.07	58.02	10.06	0.617
CD8 ⁺ CTLA4 ⁺	4.46	4.23	0.23	0.961
CD8 ⁺ CTLA4 ⁺ CD28 ⁺	18.03	23.26	-5.23	0.672
CD8 ⁺ CD28 ⁺	64.75	60.34	4.41	0.776
CD4 ⁺ PD1 ⁺	42.79	42.99	-0.20	0.989
CD8 ⁺ PD1 ⁺	43.70	56.01	-12.31	0.509
CD4 ⁺ CD154 ⁺	1.25	4.78	-3.52	0.005
CD8 ⁺ CD154 ⁺	0.24	0	0.24	0.332
CD4 ⁺ CD56 ⁺	9.94	33.81	-23.87	0.016
CD8 ⁺ CD56 ⁺	8.38	14.85	-6.47	0.325
CD4 ⁺ CD28 ⁻ PD1 ⁻	4.88	11.20	-6.32	0.281
CD4 ⁺ CD28 ⁻ PD1 ⁺	4.88	25.05	-20.17	0.094
CD4 ⁺ CD28 ⁺ PD1 ⁻	51.06	44.74	6.31	0.730
CD4 ⁺ CD28 ⁺ PD1 ⁺	39.19	19.01	20.17	0.125
CD8 ⁺ CD28 ⁻ PD1 ⁻	11.40	9.12	2.28	0.637
CD8 ⁺ CD28 ⁻ PD1 ⁺	5.46	7.27	-1.80	0.610
CD8 ⁺ CD28 ⁺ PD1 ⁻	47.15	36.12	11.03	0.463
CD8 ⁺ CD28 ⁺ PD1 ⁺	35.98	47.48	-11.50	0.499
CD4 ⁺ CD28 ⁺ CD56 ⁻	85.70	54.21	31.49	0.064
CD4 ⁺ CD28 ⁺ CD56 ⁺	2.74	7.70	-4.96	0.168
CD4 ⁺ CD28 ⁻ CD56 ⁺	2.45	15.76	-13.31	0.027
CD8 ⁺ CD28 ⁺ CD56 ⁻	75.52	72.22	3.30	0.613
CD8 ⁺ CD28 ⁺ CD56 ⁺	3.99	9.12	-5.13	0.231
CD8 ⁺ CD28 ⁻ CD56 ⁺	1.68	1.18	0.50	0.725

SUPPLEMENTARY TABLE S3. PERIPHERAL BLOOD IMMUNOPHENOTYPING DATA COMPARING 13 IMMUNE CHECKPOINT INHIBITOR-INDUCED THYROIDITIS PATIENTS (N=7 FROM A PREVIOUS STUDY AND N=6 FROM THE CURRENT STUDY) WITH 44 HEALTHY CONTROLS

<i>Immune cells (cells/μL)</i>	<i>ICI-induced thyroiditis at diagnosis (n=13)</i>	<i>Healthy volunteers (n=44)</i>	<i>Difference of means</i>	<i>p-value (t-test)</i>	<i>Melanoma, PTC on pembrolizumab</i>
Granulocytes	2678	3076	-398.0	0.240	3184.3
Mononuclear cells	2140.34	2108.0	32.34	0.863	2735.23
Lymphocytes (CD14 ⁻)	1528	1600	-72.33	0.651	2356.72
CD3 ⁺ T lymphocytes	1085	1116	-31.18	0.800	1720.71
CD19 ⁺ B lymphocytes	134.2	218.8	-84.58	0.036	239.21
CD16 ⁺ CD56 ⁻ NK cells	31.86	20.07	11.79	0.023	22.54
CD56 ⁺ CD16 ⁺ NK cells	160.20	147.40	12.76	0.598	232.99
CD56 ⁺ CD16 ⁻ NK cells	20.31	17.98	2.34	0.639	55.77
CD3 ⁺ CD56 ⁺ cells	78.92	38.39	40.53	0.003	98.66
Lineage negative cells	95.02	78.15	16.86	0.101	83.65
CD4 ⁺ T lymphocytes	675.70	757.30	-81.54	0.422	995.48
CD8 ⁺ T lymphocytes	352.0	323.2	28.79	0.552	678.02
CD4 ⁺ CD8 ⁺ T lymphocytes	16.98	10.37	6.60	0.045	20.79
CD4 ⁻ CD8 ⁻ T lymphocytes	40.16	25.20	14.96	0.012	26.41
CD4/CD8 ratio	2.12	2.85	-0.73	0.199	1.47
Gamma-delta T lymphocytes	34.92	16.86	18.06	0.005	23.68
Monocytes (CD14 ⁺)	612.60	506.60	106.0	0.077	378.52
Classical (14 ⁺ 16 ⁻) monocytes	513.10	416.20	96.89	0.058	323.02
Intermediate (14 ⁺ 16 ⁺) monocytes	59.41	37.31	22.09	0.021	29.57
Nonclassical (14lo16 ⁺) monocytes	32.91	42.15	-9.24	0.093	20.24
Neutrophils (15 ⁺ 16 ⁺)	2429	2880	-451.30	0.162	2922.34
Eosinophils (15 ⁺ 16 ⁻)	248.20	189.80	58.31	0.341	261.97

PTC, papillary thyroid carcinoma.